Emcure Pharmaceuticals launches 750 mg injectable to treat iron deficiency

Emcure Pharmaceuticals announced the launch of Orofer FCM 750, a new extension of its parenteral iron brand containing ferric carboxymaltose (FCM).

The new dosage variant is designed to provide a more effective and convenient option for patients with iron deficiency and iron deficiency anaemia (IDA). DCGI-approved FCM is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. It is already available in dosage forms 1000mg/ 20ml and 500mg/ 10ml single-use vials. With this latest launch, Orofer FCM will also be available as a 750mg/15ml dosage form recommended for treatment of patients with Hemoglobin less than 10 g/dl & bodyweight between 35 kg to 70kg. IDA is a significant burden for women, especially during later trimesters of pregnancy and secondary to postpartum hemorrhage (PPH). Approximately 36% of maternal deaths are attributed to PPH1 as per Indian studies.

Anil Kothiyal, President India Business at Emcure Pharmaceuticals said “We feel satisfied to introduce Orofer FCM 750 to help address this significant burden of IDA in India. This bolsters our commitment to providing innovative and effective solutions to meet the healthcare needs of patients in India. Orofer FCM will be available in leading pharmacies and hospitals shortly”

In April 2018, the Intensified National Iron Plus Initiative (I-NIPI) operational guidelines for the "Anemia Mukt Bharat" Programme recommended FCM as the first-line treatment for severe and selected cases of mild-to-moderate anemia in pregnant women in India.



Ready to Master Stock Valuation? ET’s Workshop is just around the corner!